Gabelli & Co Investment Advisers’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Gabelli & Co Investment Advisers’s Portfolio PRTK Stock Details PRTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-306,950	Closed	-$678K	–	275
2023 Q2	$678K	Buy	+306,950	New	+$637K	0.11%	111

Gabelli & Co Investment Advisers's PRTK Position: Q3 2023 in Review

Gabelli & Co Investment Advisers sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q3 2023, closing a stake of 306,950 shares — an estimated $678K sold.

Gabelli & Co Investment Advisers first reported a position in PRTK in Q2 2023 and held it in 1 quarter. The position peaked at $678K in Q2 2023. 0 funds tracked by Wall St. Rank hold PRTK as of Q3 2023.

Gabelli & Co Investment Advisers reported no remaining Paratek Pharmaceuticals, Inc. position as of Q3 2023 after selling out during the quarter.
Gabelli & Co Investment Advisers sold 306,950 Paratek Pharmaceuticals, Inc. shares in Q3 2023, an estimated $678K.
Gabelli & Co Investment Advisers first reported a position in Paratek Pharmaceuticals, Inc. in Q2 2023 and held it in 1 quarter.
Gabelli & Co Investment Advisers's Paratek Pharmaceuticals, Inc. position peaked at $678K in Q2 2023.
0 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q3 2023.

Based on Gabelli & Co Investment Advisers's 13F filing for Q3 2023, filed 8 Nov 2023.